Sun Pharma Turnover: Key Factors Driving Its Revenue

Every household in India relies on essential daily products, such as Revital, Suncros, and Volini, that help them during difficult moments. But do you know who the manufacturer of such good products is? It’s none other than Sun Pharmaceutical Ltd. The company produces various products related to health and wellness. The company has emerged as one of the leading pharmaceutical companies in India, which makes people wonder about Sun Pharma turnover.

This blog covers Sun Pharma’s history, growth, turnover, driving factors, and major revenue sources behind the significant growth of the company. Let’s delve into the blog to understand it completely. 

History and Growth of Sun Pharmaceuticals Industries Ltd.

Sun Pharmaceuticals Limited was established in 1983 by Mr Dilip Shanghvi, who is the founder and the Executive Chairman of the Board. During its establishment, the company began its commercial operations in Calcutta with five psychiatric products, while setting up its first manufacturing facility for tablets and capsules in Vapi, Gujarat.

From 1987 to 1994, Sun Pharma expanded its portfolio in cardiology, established its inaugural research centre in 1991, and achieved a significant milestone with its Initial Public Offering (IPO) in 1994. 

Over the period 1995 to 2000, the company focused on scaling its business globally and prioritising international customers, which boosted Sun Pharma’s turnover. It made investments in Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) and  MJ Pharma in 1997, marking a big step towards global expansion. Sun Pharmaceuticals Ltd.’s acquisition of Pradeep Drug Company further boosts its position in India. 

Between 2001 and 2010, Sun Pharma merged with several conglomerates, established additional companies, expanded its manufacturing footprint, and created a global presence. 

During the years 2011 to 2020, the company continued to expand its global presence across the United States, China, Russia, and Japan. During 2019, Sun Pharmaceuticals celebrated the 25th anniversary of its listing on the Indian Stock Exchanges with dedication, innovation, and expansion. 

From 2021 to 2024, the company entered India’s nutrition bar segment with Revital NXT.  In 2024, Sun Pharmaceutical was included in the S&P Global Sustainability Yearbook. 

Over the years, the company has achieved various milestones that have contributed to Sun Pharma’s turnover. 

Sun Pharma Turnover: Revenue Analysis

Sun Pharma turnover continues to increase with rapid growth from 2012 to 2025. The company’s financial reports show the revenue, which is the total amount of income that a company generates from the sale of goods or services.   

Here is the table representing the revenue analysis of Sun Pharmaceuticals. 

The table above shows that the company’s turnover decreased by 15.15% in 2017 compared to 2016. However, after 2017, Sun Pharma started to rise again with a rapid growth continuing till 2025.   

What Drives Sun Pharma’s Billion-Dollar Turnover?

Sun Pharma turnover is driven by various factors, including speciality portfolio, dominance in India, strong presence in the US market, acquisitions, and R&D investment, along with diversification.  Let’s discuss them briefly: 

• The company’s sales diversity in speciality products in dermatology, ophthalmology, and oncology has increased, contributing to a significant share of the US revenue. 
• It serves as a deep distribution network driven by a strong presence in chronic therapies across cardiology, psychiatry, neurology, and gastroenterology in India. 
• The company generates most of its revenue from the US market, which accounts for approximately 29–31% of total revenue, with India formulations contributing a comparable share. 
• Sun Pharma turnover boosts through its acquisitions with other pharmaceutical companies, along with consistent investments in R&D, around 6-8% of its global revenue, with a plan to expand it further. Similar growth can also be observed among the top pharma companies in India, focusing on innovation and expanding their reach to global markets. 
• The company operates in more than 100 countries, including the US and India, with major sales from emerging markets and the rest of the world.  

A Leader in Speciality Generic Pharmaceuticals & CSR Excellence

Sun Pharmaceuticals Ltd. is an international leader in speciality generic pharmaceuticals. The company has 41 manufacturing facilities globally as of 2025 and delivers high-quality medicines to more than 100 countries, including all markets. 

It produces an extensive range of medicines developed for both chronic and acute conditions. Additionally, Sun Pharma is also committed to CSR, which helps communities meet immediate demands and provides long-term growth. They also improved educational opportunities by developing schools and implementing technology-driven learning programs. 

Sun Pharma turnover has been rising with continued growth due to its fast and quality services along with CSR initiatives. 

Frequently Asked Questions

1. How many divisions are in Sun Pharma? 

Sun Pharma’s portfolio includes a wide range of therapeutic areas. It has 43 facilities globally across injectables, sprays, ointments, creams, liquids, tablets, capsules, etc. 

2. What is Sun Pharma famous for? 

Sun Pharma is the world’s fourth-largest speciality generic pharmaceutical company, famous for its products like Revital H, Volini, etc. 

3. Which company recently merged with Sun Pharma? 

Taro Pharmaceuticals Industries Ltd. merged with Sun Pharma, making Taro a wholly owned subsidiary of the company. 

4. Why was Ranbaxy sold to Sun Pharma Ltd.?

Ranbaxy was sold to Sun Pharma Ltd. for $3.2 billion due to its regulatory issues. 

5. What is the rank of Sun Pharma in India? 

Sun Pharma ranks as the largest pharmaceutical company in India by market capitalisation.